Blue Faery

Blue Faery's mission is to prevent, treat and cure primary #livercancer
Visit us on LinkedIn:

[CURE Today @cure_today]

While the majority of liver cancer cases are preventable, it's still the 3rd leading cause of cancer deaths worldwide.

Join @bluefaeryliver at Houston Methodist Hospital (@MethodistHosp) on April 25 for a free lunch and discussion.

Register here: https://t.co/6Iw2Xoiibl

[HCC CONNECT powered by COR2ED @hccconnectinfo]

LEVIATHAN publication snapshot

📺 Prof. David Pinato (@DJPinato) summarises key findings from the LEVIATHAN study, evaluating lenvatinib versus sorafenib as 2nd line treatment post atezolizumab + bevacizumab for HCC

>> Endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets

View/download the infographic: https://t.co/2jfN8TNIot

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

#MedEd #HCC

[PeerView @PeerView]

Missed our #livercancer event during #GI26? Drs. Galle, El-Khoueiry (@DrElkhoueiry), & Kelley met to discuss the evolution of systemic treatment options across the disease spectrum. Watch today! https://t.co/7ftQB2BPg2 #oncology #MedEd #HCC @BlueFaeryLiver

[HCC CONNECT powered by COR2ED @hccconnectinfo]

LEVIATHAN publication snapshot

>> Expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for HCC

📺 from Prof. David Pinato (@DJPinato)

>> Programme endorsed by @EuropeLiver, @GlobalLiver, @BlueFaeryLiver & @ESDO_tweets

Get the clinical takeaways & view the infographic: https://t.co/2jfN8TNayV

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

#MedEd #HCC

[HCC CONNECT powered by COR2ED @hccconnectinfo]

Get expert insights on the LEVIATHAN publication

>> Evaluating lenvatinib versus sorafenib as 2nd line treatment post atezolizumab plus bevacizumab for #HCC

📺 Prof. David Pinato (@DJPinato) discusses key findings & implications for practice

View/download the infographic: https://t.co/2jfN8TNIot

🤝 Programme endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

#MedEd #HCC

[HCC CONNECT powered by COR2ED @hccconnectinfo]

Insights from the LEVIATHAN study 📜

Tap the image to enlarge the infographic 🔍

>> LEVIATHAN: evaluating lenvatinib versus sorafenib as 2nd line treatment post atezolizumab plus bevacizumab for #HCC

Prof. David Pinato (@DJPinato) summarises key findings from the publication and discusses the implications for clinical practice

Watch his video: https://t.co/afhsdOiWmH

🤝 Endorsed by @EuropeLiver, @BlueFaeryLiver, @GlobalLiver & @ESDO_tweets

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

#MedEd #OncTwitter

[PeerView @PeerView]

Are you up on the latest data for #livercancer care? Watch Drs. Galle, El-Khoueiry (@DrElkhoueiry), & Kelley discuss how recent systemic therapy developments are changing tx paradigms across the disease spectrum: https://t.co/7ftQB2Cn5A #GI26 #oncology #MedEd #HCC @BlueFaeryLiver

[HCC CONNECT powered by COR2ED @hccconnectinfo]

LEVIATHAN publication

Get expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for #HCC

📺 from Prof. David Pinato (@DJPinato)

🤝 Endorsed by @EuropeLiver, @BlueFaeryLiver, @ESDO_tweets & @GlobalLiver

View/download the infographic: https://t.co/2jfN8TNayV

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.

#MedEd #Oncology

[Blue Faery @BlueFaeryLiver]

International Commission Calls For Action Against Hepatocellular Carcinoma @kinkidaigakuPR https://t.co/ambBo99sFo #liverhealth #livercancer #liverdisease

[Blue Faery @BlueFaeryLiver]

Incidence of Early-Onset Liver Cancer in Younger Patients Decreasing @CarleIllinoisCollegeofMedicinehttps://vist.ly/4qn54 #liverhealth #livercancer #liverdisease

[Blue Faery @BlueFaeryLiver]

🖤 Black communities face higher liver cancer risks. Awareness can save lives.
For Black History Month, join our FREE workshop TONIGHT with Dr. Rebecca Jones to learn prevention & early warning signs.
🎟️ Register now:
https://t.co/kZvuk5Cgd9
Knowledge is power. Share it.
#liverhealth #livercancer #liverdisease #loveyourliver #blackhistorymonth

[Salud America! @SaludAmerica]

TONIGHT!

Join @bluefaeryliver for the #LoveYourLiver workshop on 2/5/26 featuring Dr. Rebecca Jones of @UTHealthSA!

Register: https://t.co/NZ6VUQEJEH

[Blue Faery @BlueFaeryLiver]

Targeting ETV5 May Slow Tumor Progression in Hepatocellular Carcinoma https://t.co/xJDMwXsxws #liverhealth #livercancer #liverdisease

[Salud America! @SaludAmerica]

On 2/5/26, join @bluefaeryliver for the #LoveYourLiver workshop featuring Dr. Rebecca Jones of @UTHealthSA!

Register: https://t.co/NZ6VUQEJEH

[Blue Faery @BlueFaeryLiver]

Feb. 5 Event: 💙 #LoveYourLiver this #February! 💙 Register for @bluefaeryliver’s upcoming LoveYourLiver #BlackHistoryMonth Community Event, featuring Dr. Rebecca Jones, at https://t.co/sWuqXqOWi3 👆 #HealthEquity #liverdisease #livercancer #liverhealth

[HCC CONNECT powered by COR2ED @hccconnectinfo]

Expert insights on the LEVIATHAN publication

>> Evaluating lenvatinib versus sorafenib as 2nd line treatment post atezolizumab plus bevacizumab for HCC

📺 Prof. David Pinato (@DJPinato) discusses key findings & implications for practice

View the infographic: https://t.co/2jfN8TNIot

>> Endorsed by @EuropeLiver, @ESDO_tweets, @BlueFaeryLiver & @GlobalLiver

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content. This content is intended for HCPs only

#MedEd #HCC

[Blue Faery @BlueFaeryLiver]

MRI Shows Promise Profiling Hepatocellular Carcinoma Tumors @YaleMed https://t.co/Mh9llAX9d1 #liverhealth #livercancer #liverdisease

[Salud America! @SaludAmerica]

Join @bluefaeryliver for the #LoveYourLiver workshop on 2/5/26 featuring Dr. Rebecca Jones of @UTHealthSA! https://t.co/IeZAMpajZk

[Blue Faery @BlueFaeryLiver]

Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma @US_FDA @AkesoInc https://t.co/jvSSRuFf5l #liverhealth #livercancer #liverdisease

[HCC CONNECT powered by COR2ED @hccconnectinfo]

LEVIATHAN publication snapshot

>> Expert insights on 2nd line treatment selection post atezolizumab + bevacizumab for HCC

📺 from Prof. David Pinato (@DJPinato)

>> Programme endorsed by
@EuropeLiver, @BlueFaeryLiver, @GlobalLiver
& @ESDO_tweets

This programme is supported by an independent educational grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content.